Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alliance/HMR LiquiVent pivotal trial in adult acute respiratory failure to begin by mid-year.

Executive Summary

ALLIANCE/HMR LIQUIVENT ADULT PIVOTAL TRIAL TO BEGIN BY MID-1997 in adults with acute hypoxemic respiratory failure, San Diego-based Alliance predicted. Hoechst Marion Roussel is collaborating with Alliance on the development of LiquiVent (perflubron), an oxygen-carrying liquid for what Alliance terms "partial liquid ventilation," in which LiquiVent is administered "directly into the lungs of a patient who is being supported by a mechanical ventilator." HMR will market LiquiVent; the collaboration is worth up to $100 mil. to Alliance ("The Pink Sheet" March 11, 1996, T&G-10).
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS029709

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel